Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
View Patent ↗Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as Leishmania major farnesyl diphosphate synthase (FPPS) inhibition, Dictyostelium discoideum growth inhibition, human gamma delta T cell activation, and bone resorption. The applicability of bisphosphonate compounds in the context of parasitic infections, for example against trypanosomes, is disclosed. Further potential applications of the invention are disclosed regarding the treatment of one or more conditions such as bone resorption disorders, cancer, bone pain, infectious diseases, and in immunotherapy.
1. A compound of formula CA1:
or a pharmaceutically acceptable salt thereof; wherein:
X is H
n is 1,2, or 3;
R 1 and R 5 are both hydrogens and R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, halogen, an optionally substituted alkyl group having 4-20 carbon atoms, an optionally substituted alkenyl group having 2-20 carbon atoms, an —OR group, an optionally substituted aryl group and an optionally substituted arylalkyl group, where R is selected from an optionally substituted alkyl group having 1-20 carbon atoms; and
R 6 and R 7 , independently, are selected from the group consisting of a hydrogen, a halogen, a —N(R′) 2 , or —SR′ group, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkoxy group, and an optionally substituted aryl group, where each R′, independently, is selected from H, an optionally substituted alkyl group and an optionally substituted aryl group,
wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of a halogen, an optionally substituted alkyl group having 4-20 carbon atoms, an optionally substituted alkenyl group having 2-20 carbon atoms, an —OR group;
and wherein R is selected from an optionally substituted alkyl group having 1-20 carbon atoms, an optionally substituted aryl group and an optionally substituted aryl alkyl group.
2. The compound of claim 1 , wherein n is 1.
3. The compound of claim 2 , wherein R 6 and R 7 are both hydrogens.
4. The compound of claim 1 , wherein R 1 and R 5 are both hydrogens.
5. The compound of claim 1 , wherein the alkyl, alkenyl or aryl groups are optionally substituted with one or more halogens, —CN, —COOR″, —OR″, —COR″, —OCOOR″, —CON(R″) 2 , —OCON(R″) 2 , —N(R″) 2 , —NO 2 , —SR″, —SO 2 R″, —SO 2 N(R″) 2 , —SOR″, alkyl, alkenyl, or aryl groups, where each R″, independently, is hydrogen, an alkyl group, alkenyl group or aryl group.
6. The compound of claim 1 , wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of an optionally substituted alkyl group having 4-20 carbon atoms, an optionally substituted alkenyl group having 2-20 carbon atoms, and an —OR group where R is selected from an optionally substituted alkyl group having 1-20 carbon atoms.
7. The compound of claim 6 , wherein n is 1 and R 6 and R 7 are both hydrogens.
8. The compound of claim 1 , wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of an optionally substituted alkyl group having 4-20 carbon atoms, and an —OR group where R is selected from an optionally substituted alkyl group having 4-20 carbon atoms.
9. The compound of claim 1 , wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of an optionally substituted aryl group and an optionally substituted aryl alkyl group.
10. The compound of claim 9 , wherein the aryl groups are optionally substituted with one or more halogens, alkyl groups, alkoxy groups or hydroxy groups.
11. The compound of claim 9 , wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of an optionally substituted phenyl group and an optionally substituted phenylmethyl group.
12. The compound of claim 11 , wherein n is 1 and R 6 and R 7 are both hydrogen.
13. The compound of claim 1 , wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of an —OR group where R is selected from an optionally substituted alkyl group having 4-20 carbon atoms.
14. The compound of claim 13 , wherein n is 1 and R 6 and R 7 are both hydrogen.
15. The compound of claim 1 , wherein at least one of R 2 , R 3 or R 4 is selected from the group consisting of an —OR group where R is selected from an alkyl group having 4-20 carbon atoms.
16. The compound of claim 15 , wherein n is 1 and R 6 and R 7 are both hydrogen.
17. The compound of claim 1 , wherein n is 1, all of R 1 , R 3 -R 7 are hydrogens, and R 2 is selected from the group consisting of optionally substituted alkyl groups having 4-20 carbon atoms, optionally substituted alkoxy groups having 4-20 carbon atoms and optionally substituted phenyl groups.
18. The compound of claim 17 , wherein optional substitution is substitution by one or more halogens, alkyl groups, alkoxy groups or hydroxy groups.
19. The compound of claim 1 , wherein n is 1, all of R 1 , R 3 -R 7 are hydrogens and R 2 is an optionally substituted alkyl group having 4-20 carbon atoms.
20. The compound of claim 1 , wherein n is 1, all of R 1 , R 3 -R 7 are hydrogens and R 2 is an alkyl group having 4-20 carbon atoms.
21. The compound of claim 1 , wherein n is 1, all of R 1 , R 3 -R 7 are hydrogens and R 2 is an alkyl group having 4-10 carbon atoms.
22. The compound of claim 1 , wherein n is 1, all of R 1 , R 3 -R 7 are hydrogens and R 2 is an alkyl group having 10-20 carbon atoms.
23. A therapeutic composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
24. A pharmaceutical composition comprising a compound of claim 19 and a pharmaceutically acceptable carrier.
25. A method of treating a bone resorption disorder comprising administering to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 .
26. A method of treating an infectious disease comprising administering to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 wherein the infection is due to Trypanosoma or Leishmania parasites.
27. A method for stimulating γδ T cells which comprises the step of contacting an effective amount of a compound of claim 1 with γδ T cells.